## Background: Despite improvements in the treatment of pediatric acute lymphoblastic leukemia, approximately one in five patients will develop recurrent disease. the majority of these patients do not survive. this limited institution study sought to improve event-free survival (efs) by intensifica
Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia
✍ Scribed by G. Henze; R. Fengler; R. Hartmann; R. Dopfer; U. Göbel; N. Graf; H. Jürgens; D. Niethammer; J. Ritter; G. Schellong; W. Siegert
- Publisher
- Springer
- Year
- 1989
- Tongue
- English
- Weight
- 318 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Localized bone marrow relapse is rare in acute lymphoblastic leukemia. Discordant bone marrow specimens were found in an 11-year-old asymptomatic girl who had been in remission for six years and off chemotherapy for 2 1/2 years. One bone marrow sample showed marked leukemic infiltration, whereas mar
Thirty-four children with acute lymphoblastic leukaemia (ALL) in relapse or resistant to initial induction received combination chemotherapy with prednisolone, vincristine, l-asparaginase, and daunorubicin. L-asparaginase was given subcutaneously on alternate days for four weeks and was well tolerat
## Abstract In a retrospective review which covered the whole Dutch childhood population of approximately 3 million children we studied the prognosis in 164 children with acute lymphoblastic leukemia (ALL) who were initially treated between 1973 and 1983, and who had an isolated bone marrow relapse